本出版物总结了 2024 年欧洲泌尿外科协会 (EAU) 关于非肌层浸润性膀胱癌 (NMIBC)、TaT1 和原位癌指南的更新。除非另有说明，本文提供的信息仅限于尿路上皮癌。目的是为 NMIBC 的临床管理提供实用建议，重点关注临床表现。对于 2024 年 NMIBC 指南，通过对文献进行结构化评估，识别、整理和评估了新的相关证据。检索的数据库包括 Medline、EMBASE 和 Cochrane 图书馆。专家组制定了指南中的建议，以优先考虑临床上重要的护理决策。每项建议的强度是根据替代管理策略的理想和不良后果之间的平衡、证据的质量（包括估计的确定性）以及患者价值观和偏好的性质和可变性来确定的。关键建议强调了重要性NMIBC 患者的彻底诊断、治疗和随访。该指南强调了定义患者风险分层并对其进行适当治疗的重要性。2024 年 EAU 指南的概述为 NMIBC 的风险因素、诊断、分类、预后因素、治疗和随访提供了宝贵的见解。这些指南旨在有效融入临床实践。版权所有 © 2024 欧洲泌尿外科协会。版权所有。

This publication represents a summary of the updated 2024 European Association of Urology (EAU) guidelines for non-muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ. The information presented herein is limited to urothelial carcinoma, unless specified otherwise. The aim is to provide practical recommendations on the clinical management of NMIBC with a focus on clinical presentation.For the 2024 guidelines on NMIBC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences.Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with NMIBC. The guidelines stress the importance of defining patients' risk stratification and treating them appropriately.This overview of the 2024 EAU guidelines offers valuable insights into risk factors, diagnosis, classification, prognostic factors, treatment, and follow-up of NMIBC. These guidelines are designed for effective integration into clinical practice.Copyright © 2024 European Association of Urology. All rights reserved.